INTRODUCTION
negative cells with TLR2, but not with TLR1 or TLR4, made these cells responsive to LPS. 6, 7 Soon after, using a similar transfection system, it was discovered that TLR2 also serves as the receptor for both Gram-positive and Gram-negative bacteria, mycobacteria, Mycoplasma, and spirochetes, and their PGN, lipoteichoic acid (LTA), lipoarabinomannan, and lipoprotein cell wall or cell membrane components. [8] [9] [10] [11] [12] [13] [14] Subsequent work with TLR2 and TLR4 knockout mice indicated that TLR2 serves as the primary receptor for Gram-positive bacteria and their cell wall components, whereas TLR4 (but not TLR2) as the primary LPS receptor, because TLR2 (but not TLR4) knockout mice are unresponsive to Gram-positive bacteria, 15 whereas TLR4 (but not TLR2) knockout mice are unresponsive to Gramnegative bacteria and LPS. 15, 16 This notion is consistent with the hyporesponsiveness to LPS, but not to Gram-positive bacteria, of C3H/HeJ and in C57BL/10ScCr mice, which have a mutation in the Tlr4 gene, 17, 18 and with the responsiveness of TLR2-deficient cells to LPS, but not to Gram-positive bacteria. 19 Most recent studies indicate that, by itself, TLR2 does not function as an LPS receptor. Highly purified proteinfree LPS or lipid A do not activate TLR-negative cells transfected with TLR2. 20, 21 In fact, the responsiveness of TLR2-transfected cells to various endotoxic LPS preparations, LPS mutants, and LPS partial structures does not correlate with the LPS structure and endotoxicity, but with the extent of protein contamination of LPS. 21 In the earlier studies, the responses of TLR2-transfected cells to LPS required very high concentrations of LPS (compared to the concentrations of LPS needed to activate macrophages). [6] [7] [8] [9] 22 Moreover, the most 'active' LPS preparations used in those studies (e.g. LPS from Escherichia coli LCD25 or O127, or ReLPS from E. coli) had the highest protein contamination, 21 whereas, highly purified LPS and lipid A preparation, devoid of any detectable protein (>99.99% pure) do not activate cells through TLR2 alone or in conjunction with CD14. 21 These results confirm that TLR2 by itself or in conjunction with CD14 does not function as an LPS receptor. 20, 21 However, TLR2 by itself or in conjunction with CD14 does serve as a cell-activating receptor for PGN, lipoteichoic acid (LTA), synthetic lipopeptide (an analog of microbial lipoproteins), as well as the entire Gram-positive and Gram-negative bacteria ( Fig. 1 ). 7, 8, 21 
Discovery of MD-2 and its requirement for TLR4 responses
Despite the genetic evidence from LPS-hyporesponsive mice 17, 18 and TLR4 knockout mice, 15, 16 clearly showing the requirement for TLR4 in LPS responses, TLR4 by itself or in conjunction with CD14 does not function as an LPS receptor, because transfection of TLR4-negative cells with TLR4 (with or without CD14) does not make these cells responsive to LPS. [6] [7] [8] [9] These data indicate that another molecule is required for TLR4-mediated responsiveness to LPS. Indeed, it was recently discovered that to function as an LPS receptor, TLR4 requires a helper molecule, MD-2. 23 MD-2 is a 160 amino acid protein that is associated with TLR4 on the cell surface and enables TLR4 to respond to LPS. 23, 24 The discovery of MD-2 explained why TLR4-transfected cells (in which MD-2 is not expressed) are unresponsive to LPS 7-9,11 and supports the proposed function of the TLR4-MD-2 complex as the LPS receptor.
MD-2 enables TLR2 to respond to LPS
Because TLR4 by itself does not respond to LPS and because TLR4 requires MD-2 to respond to LPS, 23 it was also possible that TLR2, which by itself does not respond to pure LPS, could also require MD-2 to respond to LPS. Indeed, human 293 cells co-transfected with TLR2, CD14, and MD-2, became highly responsive to all LPS preparations and LPS partial structures, including highly purified protein-free LPS, ReLPS, and lipid A preparations that do not activate these cells when transfected only with TLR2 and CD14. 21 In the presence of MD-2, LPS preparations efficiently activate TLR2/CD14-transfected cells even at 0.1-1 ng/ml. 21 Thus, MD-2 enhances 10 4 -10 5 times the responses of TLR2/CD14 transfected cells to several purified LPS preparations. Therefore, MD-2 enables very sensitive TLR2/CD14-mediated recognition of protein-free LPS and LPS partial structures and enhances responses to all endotoxic LPS ( Fig. 1 ). 21 
MD-2 enhances TLR2-mediated responses to both Gram-positive and Gram-negative bacteria and their cell wall components
Gram-positive and Gram-negative bacteria and their PGN and LTA cell wall components can activate cells 402 Dziarski, Gupta through TLR2 in the absence of MD-2. 8, 9, 11 However, MD-2 enhances TLR2-mediated responses to PGN, LTA, and both Gram-positive and Gram-negative intact bacteria, when co-transfected into 293 cells together with TLR2 (and CD14). 21 TLR2 by itself is also responsive to lipopeptide, but this response is not enhanced by MD-2 ( Fig. 1 ). 21 Thus, TLR2 is able to respond to several (but not all) stimuli without MD-2, and MD-2 enhances its responses to most of these stimuli. Moreover, MD-2 also enables TLR2 to respond to stimuli (e.g. protein-free LPS) to which TLR2 by itself is not responsive. Therefore, MD-2 both broadens the spectrum of stimulants that can activate cells through TLR2 and enhances the responsiveness of TLR2 to stimulants that do not absolutely require MD-2 for TLR2-mediated cell activation.
MD-2 enables TLR4-mediated responses to LPS, LPSpartial structures, Gram-negative bacteria, and LTA, but not to PGN, lipopeptide, and Gram-positive bacteria
TLR4 by itself or together with CD14 is unresponsive to both Gram-negative and Gram-positive bacteria and their components. [6] [7] [8] [9] 11, 21 MD-2, when co-transfected into 293 cells together with TLR4 (and CD14), enables TLR4 to recognize a large variety of LPS, LPS partial structures, and lipid A, as well as intact Gram-negative bacteria and LTA from Gram-positive bacteria. 21 However, MD-2 does not enable TLR4 to respond to Gram-positive bacteria, PGN, and lipopeptide. 21 Thus, TLR4 has a narrower specificity than TLR2, and, in contrast to TLR2, TLR4 has an absolute requirement for MD-2 for cell activation by all stimulants (Fig. 1) . However, MD-2 does not make all TLRs responsive to bacterial stimulants, because cells co-transfected with TLR1, CD14, and MD-2 are unresponsive to all of the above bacterial stimulants. 21 These data on the specificity of TLR4 responses are consistent with the experiments on TLR4 knockout mice, 15, 16 which showed that TLR4 responds to Gramnegative LPS and Gram-positive LTA.
These results suggest that TLR4-MD-2 complex is specific for glycolipids, which is a structural feature shared by both LPS and LTA, and also suggest the requirement for both the glycan and the lipid components of LPS and LTA, because neither detoxified (de-lipidated) LPS, nor the lipidcontaining lipopeptide (that lacks the glycan component) could stimulate cells through the TLR4-MD-2 complex. 21 These results also suggest that LTA does not contribute to the responses to intact Gram-positive bacteria, because cells co-transfected with TLR4, CD14, and MD-2 are responsive to isolated LTA, but are unresponsive to LTAcontaining Gram-positive bacteria. This lack of cell activation by intact bacteria may be due to the anchoring of the lipid part of LTA in the bacterial cell membrane, which is located underneath the thick PGN layer.
MD-2 associates with both TLR2 and TLR4, and MD-2 and TLR2 or TLR4 enhance each other's expression
One possible mechanism of MD-2 enhancement of TLR2-and TLR4-mediated responses could be physical association of MD-2 with TLR2 and TLR4, because it was shown before that MD-2 physically associates with TLR4. 23, 24 Indeed, MD-2 also physically associates with TLR2, as determined by co-precipitation of MD-2 with TLR2 in transiently transfected 293 cells, but this association is much weaker than with TLR4 (Fig. 2) . 21 MD-2 also enhances expression of both TLR2 and TLR4 proteins in transiently transfected 293 cells, and TLR2 and TLR4 also enhance expression of MD-2 protein (Fig. 2) . 21 Therefore, these results suggest that MD-2 enables or enhances TLR2-and TLR4-mediated responses by physically associating with TLR2 and TLR4 and by increasing the amount of expressed TLR2 and TLR4 protein. The exact mechanism of this enhanced expression is unknown; but, because of the physical association of TLRs with MD-2, it may rely on a greater stability of MD-2-TLR complexes, compared with the stability of TLRs and MD-2 alone.
Why are the responses of TLR4 knockout or mutant mice different from the responses of TLR2 and TLR4 transfected cells?
The responsiveness of 293 cells transfected with TLR2 or TLR4 is different from the responsiveness of TLR4 knockout or mutant mice. TLR4 knockout or mutant mice, which have an intact Tlr2 gene, are unresponsive to LPS and LTA, thus indicating that in these mice TLR2 cannot function as an effective LPS and LTA receptor. [15] [16] [17] [18] This difference may be due to the inducible expression of TLR2 25 or due to the insufficient expression or function of MD-2 in TLR4 knockout or mutant mice. This possibility is consistent with much stronger association of MD-2 with TLR4 than with TLR2. 21 Therefore, in TLR2 knockout and mutant mice the amount of MD-2 may be sufficient to support the function of TLR4, but may not be sufficient to support the function of TLR2. Moreover, in most primary cells the expression of TLR2 is much lower than TLR4 25, 26 and the expression of TLR2 is inducible by cell stimulation. 25 Because the expression of MD-2 is enhanced by the expression of TLRs, 21 it is possible that TLR4 knockout and mutant mice have insufficient expression of MD-2, because of the lack of the enhancing effect of TLR4 on the expression of MD-2, and because of the low expression of TLR2. Insufficient expression of MD-2 and low expression of TLR2 would then explain the unresponsiveness of TLR4 knockout and mutant mice to pure LPS, which requires MD-2, but not to Gram-positive bacteria, which do not require MD-2. This hypothesis needs to be experimentally tested.
Chemokines are the highest induced pro-inflammatory mediators in human monocytes activated by both Grampositive and Gram-negative bacterial components
It is widely believed that cytokines TNF-α, IL-1, and IL-6 are the main pro-inflammatory mediators induced in the host by bacteria and their cell wall components. The analysis of expression of 600 genes activated in human monocytes by Staphylococcus aureus, PGN, LPS, and interferon (IFN)-γ revealed that the highest activated genes for pro-inflammatory mediators induced by all three bacterial stimulants are chemokine genes (IL-8 and MIP-1α), whereas cytokine genes (TNF-α, IL-1, and IL-6) are induced to a lower extent. 27 Genes for other chemokines (MIP-2α, MIP-1β, and MCP-1) are also induced higher than the cytokine genes by PGN, and as high or higher than the cytokine genes by S. aureus and LPS. This high induction of chemokine genes and secretion of chemokine proteins have been confirmed by quantitative RNase protection assay and ELISA. 27 Although genes for chemokines are the highest and genes for cytokines are the second highest induced genes by all three bacterial stimulants, each stimulus induces a unique pattern of gene expression. By contrast, expression of a completely different gene pattern is induced by a non-bacterial stimulus, IFN-γ. 27 These results are consistent with the highly inflammatory nature of bacterial infections.
TLR2 induces transcription of IL-8 through TLR2→
MyD88→IRAK→TRAF→NIK→IKK→NF-κB signal transduction pathway.
Gram-positive bacteria (Micrococcus), PGN, and LPS induce TLR2-dependent transcription of IL-8 in 293 cells. 28 A mutation within the NF-κB site in the IL-8 promoter abrogates transcriptional induction of IL-8 by these stimulants. Dominant negative mutants of MyD88, IRAK, NIK and IKK completely inhibit activation of NF-κB and expression of IL-8 gene by these stimulants. Induction of NF-κB is also partially inhibited by dominant negative TRAF6 but not TRAF2, whereas induction of IL-8 gene is partially inhibited by both TRAF6 and TRAF2. 28 Therefore, bacteria, PGN, and LPS induce TLR2-dependent activation of IL-8 gene, and this activation requires MyD88, IRAK, NIK, IKK, and NF-κB, and may also utilize TRAF6, and to a lesser extent, TRAF2 (Fig. 3 ).
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This work was supported by the US PHS Grant AI2879 from NIH. Fig. 3 . TLR2-mediated signal transduction pathway for activation of IL-8 transcription. 28 Activation of Toll-like receptor-2 (TLR2) by bacteria or bacterial cell wall components (PGN or LPS) results in recruitment of adapter molecules MyD88 (myeloid differentiation protein 88), IRAK (IL-1 receptor-associated kinase), and TRAF (TNF receptor-associated kinase), followed by activation of NIK (NF-κB inducing kinase) and IKK (IκB kinases), which phosphorylate IκB (inhibitor of κB). This releases NF-κB (nuclear factor κB), which translocates to the nucleus and activates transcription of IL-8 (interleukin-8) gene. An alternative pathway involving TRAF2, that by-passes activation of NF-κB, may also be present.
